Aardvark Therapeutics Announces Leadership Appointments

Core Insights - Aardvark Therapeutics, Inc. has appointed Derrick C. Li as Chief Business Officer and expanded Nelson Sun's role to Chief Operating Officer, effective February 9, 2026, which is seen as pivotal for the company's growth as it advances its clinical programs [1][2] Company Developments - The appointments of Derrick Li and Nelson Sun are crucial as Aardvark progresses ARD-101 through Phase 3 development for hyperphagia associated with Prader-Willi Syndrome and continues Phase 2 development of ARD-201 for obesity-related conditions [2] - Derrick Li will lead Aardvark's business development strategy, focusing on financing, licensing, partnership strategy, and corporate development initiatives [2][3] Product Pipeline - Aardvark is developing ARD-101, an oral compound in Phase 3 clinical development for treating hyperphagia associated with Prader-Willi Syndrome, and ARD-201, a planned fixed-dose combination with a DPP-4 inhibitor, through two separate Phase 2 trials [4] - Topline Phase 3 data for ARD-101 is expected in the third quarter of 2026, which is a significant milestone for the company [3]